Deal targets treatment-resistant depression market as Lilly diversifies beyond its dominant GLP-1 drug portfolio.
Eli Lilly (LLY) agreed to acquire clinical-stage biotech AtaiBeckley for $2.8 billion in cash, bolstering its neuroscience business. The deal includes BPL-003, an investigational drug for treatment-resistant depression showing strong phase 2 results.
Lilly’s GLP-1 drugs, led by Zepbound, dominate the $150 billion weight-loss market projected by analysts. The acquisition marks a strategic shift toward mental health therapies, addressing an underserved patient population.
AtaiBeckley’s pipeline complements Lilly’s existing neuroscience portfolio, positioning the company in a high-growth segment beyond obesity treatments.